Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Åke Lernmark

Principal investigator

Default user image.

An H-2 alloantiserum preserves β-cell function in mice made diabetic by low-dose streptozotocin

Author

  • V. Bonnevie-Nielsen
  • A. Lernmark

Summary, in English

The pancreatic β-cell mass and function in C57BL/KsJ mice is markedly reduced the day after the last injection of five daily injections of a subdiabetogenic, 40 mg/kg, dose of streptozotocin (STZ). In this study, we prepared an H-2 alloantiserum by injecting C57BL/6J mice (H-2b) with spleen lymphocytes from C57BL/KsJ (H-2(d)) mice. The alloantiserum given on five consecutive days, 5 h before each injection of STZ, did not prevent the initial β-cytotoxic effect of STZ detected by perfusion of the pancreas and subsequent morphometric analysis of in situ dithizone-perfused pancreas. However, 12 days after the first injection of STZ, total insulin release in response to D-glucose, total pancreatic insulin, and pancreatic glucagon was greater in the alloantiserum-treated mice compared with controls receiving normal mouse serum. It is concluded that an H-2 alloantiserum may protect the function and amounts of β-cells remaining after the initial five low-dose STZ injections.

Publishing year

1986-01-01

Language

English

Pages

570-573

Publication/Series

Diabetes

Volume

35

Issue

5

Document type

Journal article

Publisher

American Diabetes Association Inc.

Status

Published

ISBN/ISSN/Other

  • ISSN: 0012-1797